

Neurizon Strengthens Board to Support Next Phase of Growth and Value Creation

Highlights:

- **Dr Ross Murdoch appointed as Independent Non-Executive Director, effective immediately**
- **Brings deep experience in neurodegenerative disease programs and global pharmaceutical development**
- **Strengthens Board capability across commercial strategy, operational execution and value realisation**
- **Enhances expertise in United States market engagement, capital markets and international growth**
- **Supports Neurizon's next phase of clinical execution and preparation for future commercialisation of NUZ-001**
- **Dr Michael Thurn to retire from the Board as part of planned Board transition**

08 May 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce strengthening of its Board to support the Company's next phase of clinical execution, commercial readiness and long-term shareholder value creation.

Dr Ross Murdoch has been appointed as an Independent Non-Executive Director, effective immediately. His appointment reflects Neurizon's strategic focus on advancing NUZ-001 through late-stage clinical development while building the capabilities required for future commercialisation, global market engagement and value realisation.

As part of this Board transition, Dr Michael Thurn will retire from the Board effective immediately.

Appointment of Dr Ross Murdoch

Dr Murdoch is a highly experienced global pharmaceutical, biotechnology and healthcare executive with more than 30 years' experience across listed and private companies in Australia, the United States and Europe.

He brings direct experience in neurology and neurodegenerative disease programs, combined with a strong track record in commercial strategy, operational execution and value realisation across the product lifecycle.

Dr Murdoch has held senior leadership roles with AstraZeneca, GlaxoSmithKline and Shire Pharmaceuticals, spanning clinical development, global project leadership, commercial execution and strategic growth initiatives.

He also brings deep United States market experience, having lived and worked extensively in the US across both multinational pharmaceutical and emerging biotechnology companies. His experience includes US clinical development environments, capital markets engagement, strategic transactions and scaling businesses internationally. Dr Murdoch holds dual Australian and United States citizenship.

Dr Murdoch has significant ASX-listed company governance experience, having previously served as Chief Executive Officer and Managing Director of Avecho Biotechnology Limited and continuing as a Non-Executive Director. He is currently Chief Executive Officer and President of Extractas Bioscience, where he has led a significant operational transformation and growth program.

Interim Executive Chairman, Sergio Duchini said: “Neurizon is entering a pivotal stage as we progress NUZ-001 through active clinical execution in the HEALEY ALS Platform Trial, while increasingly focusing on the pathway to commercialisation and long-term value creation.

Ross brings a highly complementary skillset across neurodegenerative disease experience, clinical development and commercial execution, together with deep US market expertise and capital markets experience.

His appointment strengthens the Board’s capability to support both the delivery of near-term clinical milestones and the translation of these into meaningful outcomes for people living with neurodegenerative diseases and long-term value for shareholders.”

Dr Ross Murdoch commented: “Neurizon has generated a strong momentum and is advancing an important program in an area of significant unmet medical need.

I look forward to working with the Board and management team to support the continued development of NUZ-001 and help position the Company for its next phase of growth and value creation.”

Board Transition

As part of this Board transition, Dr Michael Thurn will retire from the Board effective immediately, following his previously announced transition from the role of Managing Director and Chief Executive Officer.

Interim Executive Chairman, Sergio Duchini said: “On behalf of the Board, I would like to sincerely thank Michael for his leadership and contribution to Neurizon during an important period in the Company’s development. Michael has played a key role in advancing NUZ-001, supporting the Company’s clinical and strategic progress, and helping position Neurizon for its next phase of growth. We thank him for his service and wish him every success in the future.”

Dr Murdoch will stand for election by shareholders at the next Annual General Meeting in accordance with the ASX Listing Rules and the Company’s Constitution.

-ENDS-

This announcement has been authorised for release by Sergio Duchini, Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited.

For any questions, comments, or further information regarding Neurizon, please email enquiries@neurizon.com, or contact:

Marketing & Corporate Affairs

Lidija Damjanovic

Marketing & Corporate Affairs

Email: lidija@neurizon.com

Phone: +61 (0) 425 700 504

Investor Relations

Henry Jordan

Six Degrees Investor Relations

Email: henry.jordan@sdir.com.au

Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited